Taysha Gene Therapies, Inc. (NASDAQ:TSHA) to Post FY2022 Earnings of ($3.66) Per Share, Jefferies Financial Group Forecasts

Taysha Gene Therapies, Inc. (NASDAQ:TSHAGet Rating) – Investment analysts at Jefferies Financial Group reduced their FY2022 EPS estimates for Taysha Gene Therapies in a research report issued to clients and investors on Monday, May 16th. Jefferies Financial Group analyst E. Yang now forecasts that the company will earn ($3.66) per share for the year, down from their previous forecast of ($3.56). Jefferies Financial Group also issued estimates for Taysha Gene Therapies’ Q4 2022 earnings at ($0.71) EPS, FY2023 earnings at ($3.04) EPS, FY2024 earnings at ($3.03) EPS, FY2025 earnings at ($1.38) EPS and FY2026 earnings at ($0.48) EPS.

A number of other equities analysts have also weighed in on the company. Zacks Investment Research lowered Taysha Gene Therapies from a “buy” rating to a “hold” rating in a research note on Wednesday, April 6th. Guggenheim decreased their target price on Taysha Gene Therapies to $22.00 and set a “na” rating on the stock in a research note on Tuesday. JMP Securities decreased their target price on Taysha Gene Therapies from $44.00 to $36.00 and set a “market outperform” rating on the stock in a research note on Friday, April 1st. Wells Fargo & Company assumed coverage on Taysha Gene Therapies in a research note on Tuesday, March 1st. They issued an “overweight” rating and a $25.00 target price on the stock. Finally, Needham & Company LLC decreased their target price on Taysha Gene Therapies to $20.00 and set a “buy” rating on the stock in a research note on Tuesday. One analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $29.64.

Shares of TSHA opened at $3.03 on Thursday. The stock has a market capitalization of $122.64 million, a price-to-earnings ratio of -0.60 and a beta of 2.23. The company has a debt-to-equity ratio of 0.39, a quick ratio of 3.08 and a current ratio of 3.08. The stock’s 50-day simple moving average is $5.16 and its 200 day simple moving average is $8.82. Taysha Gene Therapies has a 52-week low of $2.69 and a 52-week high of $26.99.

Taysha Gene Therapies (NASDAQ:TSHAGet Rating) last issued its quarterly earnings data on Monday, May 16th. The company reported ($1.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.03) by ($0.28). During the same period last year, the firm earned ($0.87) earnings per share.

Several institutional investors have recently made changes to their positions in TSHA. Renaissance Technologies LLC bought a new position in shares of Taysha Gene Therapies during the 1st quarter valued at about $1,633,000. JPMorgan Chase & Co. increased its position in shares of Taysha Gene Therapies by 85.1% during the 1st quarter. JPMorgan Chase & Co. now owns 439,804 shares of the company’s stock valued at $2,868,000 after purchasing an additional 202,245 shares during the last quarter. Vanguard Group Inc. grew its position in Taysha Gene Therapies by 14.5% during the 1st quarter. Vanguard Group Inc. now owns 1,012,164 shares of the company’s stock worth $6,599,000 after acquiring an additional 128,517 shares during the last quarter. State Street Corp grew its position in Taysha Gene Therapies by 31.8% during the 4th quarter. State Street Corp now owns 464,169 shares of the company’s stock worth $5,408,000 after acquiring an additional 111,983 shares during the last quarter. Finally, Geode Capital Management LLC grew its position in Taysha Gene Therapies by 37.8% during the 3rd quarter. Geode Capital Management LLC now owns 363,016 shares of the company’s stock worth $6,759,000 after acquiring an additional 99,574 shares during the last quarter. Hedge funds and other institutional investors own 46.05% of the company’s stock.

About Taysha Gene Therapies (Get Rating)

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis.

Featured Articles

Earnings History and Estimates for Taysha Gene Therapies (NASDAQ:TSHA)

Receive News & Ratings for Taysha Gene Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taysha Gene Therapies and related companies with MarketBeat.com's FREE daily email newsletter.